EXEL
Exelixis Inc
Nasdaq · usd
Exelixis Inc (EXEL) trades at $64.53 (-1.19%) as of 7:30:04 PM EDT on Oct 23, 2026, +11.35% over the past month. Market cap is $16.18B, with 12.7 days to cover in short interest.
Stock performance
How Exelixis Inc (EXEL) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.19%
- 1W
- +3.70%
- 1M
- +11.35%
- YTD
- +47.23%
- 1Y
- +61.37%
- 52-wk range
- $36.00 – $65.50
Key statistics
Today's trading snapshot for EXEL: day range, open, previous close, volume and market cap.
- Day range
- $63.91 – $65.20
- Open
- $65.15
- Prev close
- $65.31
- Volume
- 2.07M
- Market cap
- $16.18B
- Shares out
- 247.78M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Exelixis Inc: P/E, P/S, P/B, ROE and more.
- P/E
- 18.80
- P/S
- 6.64
- P/B
- 8.78
- P/FCF
- 13.80
- ROE
- 46.7%
- ROA
- 34.5%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 22, 2026
8-K filings
Material corporate events Exelixis Inc has disclosed to the SEC on Form 8-K.
- Business developmentsSep 11, 2026
Today, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis' new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer by three months. ... The updated Prescription Drug User Fee Act action date is March 3, 2027.
- Legal proceedingsAug 31, 2026
The Court of Appeals also dismissed as moot MSN's appeal relating to the validity of U.S. Patent No. 11,298,349 ... and vacated the portion of the district court's decision addressing that issue.
- Shareholder meetingsMay 29, 2026
On May 26, 2026, Exelixis held its Annual Meeting via live webcast. The results of the matters submitted to a stockholder vote at the Annual Meeting were as follows: 1. Election of Directors: Exelixis stockholders elected the following 11 directors to serve until the next annual meeting of stockholders in 2027.
- Shareholder returnsMay 5, 2026
On May 5, 2026, Exelixis announced that the Board of Directors authorized the repurchase of up to an additional $750 million of its common stock by December 31, 2027.
- Guidance and outlookJan 12, 2026
On January 11, 2026, Exelixis, Inc. (Exelixis or the Company) issued a press release announcing its preliminary unaudited financial results for the fiscal year ended January 2, 2026, providing financial guidance for the fiscal year ending January 1, 2027, and delivered an update on its business.
EXEL short interest
How heavily EXEL is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 12.7
- Short interest
- 28.18M
- Avg volume
- 2.23M
As of · reported to FINRA twice monthly.
EXEL news
The latest news and headlines about Exelixis Inc (EXEL).
- Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleasepositiveZacks Investment Research· Oct 22, 2026
- 2 Under-the-Radar Stocks to Buy and HoldpositiveThe Motley Fool· Oct 16, 2026
- Why Exelixis (EXEL) is a Top Growth Stock for the Long-TermpositiveZacks Investment Research· Oct 16, 2026
- Why Exelixis (EXEL) is Poised to Beat Earnings Estimates AgainpositiveZacks Investment Research· Oct 15, 2026
- Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?positiveZacks Investment Research· Sep 30, 2026
Frequently asked questions
What is the Exelixis Inc (EXEL) stock price today?
Exelixis Inc (EXEL) is trading at $64.53 (-1.19% on the day) as of 7:30:04 PM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Exelixis Inc?
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney…
What is the short interest in EXEL?
As of Sep 30, 2026, EXEL has 28.18M shares short and 12.7 days to cover.
What exchange is EXEL listed on?
Exelixis Inc (EXEL) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of EXEL with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a EXEL analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.